Oruka Therapeutics, Inc. ORKA
NASDAQ · United States · Health Technology
$83.97+0.68 (+0.82%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Oruka Therapeutics' (ORKA) lead program of long-acting IL-23 in moderate-to-severe psoriasis maintai
Oruka Therapeutics recently reported positive Week 28 data from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis, showing deepening clinical responses and a safety profile consistent with the IL-23p19 class. An interesting aspect is that placebo patients who later crossed over to ORKA-001 achieved similar response patterns, underscoring the drug’s potential effect even after delayed initiation. Next, we’ll examine how ORKA-001’s high PASI 100 and PASI 90...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.